main purpose:
1) To evaluate the safety and tolerability of SG404 for injection in patients with advanced malignant tumors.
2) To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of intravenous administration of SG404 for injection in patients with advanced malignant tumors, and to provide the basis for the dosing schedule and dosage of phase II clinical trials.
Secondary purpose:
1) To evaluate the pharmacokinetics of SG404 for injection in patients with advanced malignant tumors.
2) To evaluate the pharmacodynamics of SG404 for injection in patients with advanced malignant tumors.
3) To evaluate the immunogenicity of SG404 for injection in patients with advanced malignant tumors.
4) Preliminary evaluation of the efficacy of SG404 for injection in patients with advanced malignant tumors.
Exploratory Purpose:
To explore potential biomarkers in tumor tissue to predict the efficacy of SG404 for injection.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.